CVM

CEL SCI CORP

Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products. (via Wikipedia)

Market Cap

$25M

Live price × SEC shares (Aug 10, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.66

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

2.3

Mkt cap / shareholders' equity

Flagged input, hover for details

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q4 FY2025 Sep 30, 2025	Q1 FY2026 Dec 31, 2025	Q2 FY2026 Mar 31, 2026	Q3 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	3,703	3,677	3,767	3,650	14,797
Total operating expenses	6,033	5,369	5,326	5,557	22,285
Operating income	(6,033)	(5,369)	(5,326)	(5,557)	(22,285)
Interest expense	129	88	117	111	445
Net income	(6,101)	(5,469)	(5,466)	(5,668)	(22,704)
EPS (diluted) ($)		(0.68)	(0.67)	(0.47)	—
Weighted avg. shares (diluted)		8,016	8,138	12,116

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 14, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 61 more quarters, back to Jun 2010, with Tormere Pro.

Corporate Events (8-K)

6 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Aug 17, 2026 accepted 1:05 PM ET	5.07Shareholder vote	Document SEC ↗
Jun 16, 2026 accepted 9:03 PM ET	1.01Material agreement8.01Other events	Document SEC ↗
May 14, 2026 accepted 9:16 PM ET	1.01Material agreement	Document SEC ↗
May 13, 2026 accepted 8:44 PM ET	1.01Material agreement8.01Other events	Document SEC ↗
Nov 24, 2025 accepted 10:00 PM ET	3.03Holder rights modified	Document SEC ↗
Nov 5, 2025 accepted 9:31 PM ET	3.03Holder rights modified	Document SEC ↗
Aug 29, 2025 accepted 5:15 PM ET	1.01Material agreement8.01Other events	Document SEC ↗
Aug 25, 2025 accepted 10:00 PM ET	8.01Other events	Document SEC ↗
Jul 14, 2025 accepted 8:25 PM ET	1.01Material agreement8.01Other events	Document SEC ↗
May 23, 2025 accepted 8:16 PM ET	1.01Material agreement8.01Other events	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

49%

W/W -0.1pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Velocity Score

1.46x

Avg Daily Buying (90d)

1,111 sh/day

Baseline Daily Buying

1,822 sh/day

Unique Buyers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-08-25	2026-08-26	KERSTEN GEERT R	Director & Chief Executive Officer	Purchase	100.0K	$1.38	$138K	316.1K	View
2026-05-14	2026-05-18	KERSTEN GEERT R	Director & Chief Executive Officer	Purchase	300.0K	$1.20	$360K	311.5K	View
2026-05-13	2026-05-14	KERSTEN GEERT R	Director & Chief Executive Officer	Purchase	100.0K	$1.19	$119K	222.5K	View
2026-01-22	2026-01-26	KERSTEN GEERT R	Director & Chief Executive Officer	Purchase	38.0K	$5.26	$200K	120.8K	View
2025-12-04	2025-12-05	KERSTEN GEERT R	Director & Chief Executive Officer	Purchase	8,389	$5.96	$50K	81.8K	View

1–5 of 6

1 / 2

Gov Contracts

Agency	Amount	Awarded
Department of Defense	$1.4B	2010-06-16

Recent News

CEL-SCI reports 73.4% five-year survival in Multikine Phase 3 patient analysis

Yahoo · 2026-10-29

CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival

Yahoo · 2026-10-26

CEL-SCI Presents New Pre-Surgical Data From Its Phase 3 Trial Of Multikine At World Congress; Locally Advanced Primary Tumor With No Detectable Lymph Node Involved; Tumor Proportion Score Less Than 10%

Benzinga · 2026-10-26

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.

ChartMill · 2026-10-07

What's going on in today's session

ChartMill · 2026-10-07

12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga · 2026-10-07

A 2,082-share award brings CEL SCI CORP (CVM) CFO Patricia B. Prichep's direct holding to 19,571 shares.

Stock Titan · 2026-10-01

CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology

Yahoo Finance · 2026-09-15

CEL SCI (CVM) CEO adds 100K restricted shares to his stake

Stock Titan · 2026-08-26

CEL-SCI Reports Fiscal Third Quarter 2026 Results

Yahoo Finance · 2026-08-17

CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer

Yahoo Finance · 2026-07-13

$CVM stock is up 17% today. Here's what we see in our data.

Quiver Quantitative · 2026-07-06

CEL-SCI Announces Closing of Offering

Yahoo Finance · 2026-06-16

CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month

Stocktwits · 2026-06-15

CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia

Yahoo Finance · 2026-06-12

Informational purposes only, not investment advice.

Date	Insider	Type	Shares	Value
2026-08-25	KERSTEN GEERT R	P	100,000	$138,000
2026-05-14	KERSTEN GEERT R	P	300,000	$360,000
2026-05-13	KERSTEN GEERT R	P	100,000	$119,000
2026-01-22	KERSTEN GEERT R	P	38,023	$200,000.98
2025-12-04	KERSTEN GEERT R	P	8,389	$49,998.44

CVM

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Gov Contracts

Recent News

CEL SCI CORP (CVM)

Reporting Insiders

Factor Profile

Corporate Events (8-K)